Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 27

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 27
---
 costly and time-consuming means of accessing the capital markets, which could have a material adverse effect on our liquidity and
cash position.

Because the purchase price
per Depositary Share to be paid by the Selling Shareholder for the Depositary Shares that we may elect to sell to the Selling Shareholder
under the Purchase Agreement, if any, will fluctuate based on the market prices of our Depositary Shares at the time we make such election,
it is not possible for us to predict, as of the date of this prospectus and prior to any such sales, the number of Depositary Shares that
we will sell to the Selling Shareholder under the Purchase Agreement, the purchase price per share that the Selling Shareholder will pay
for Depositary Shares purchased from us under the Purchase Agreement, or the aggregate gross proceeds that we will receive from those
purchases the Selling Shareholder under the Purchase Agreement.

We are registering 358,750,000,000
Ordinary Shares under this prospectus. As of January 15, 2025, there were 6,685,918,922 Ordinary Shares outstanding. If all of the 358,750,000,000
Ordinary Shares offered for resale by the Selling Shareholder under this prospectus were issued and outstanding as of January 15, 2025,
such shares would represent approximately 98.2% of total number of Ordinary Shares outstanding.

The actual number of Depositary
Shares issuable will vary depending on the then current market price of our Depositary Shares sold to the Selling Shareholder in this
offering and the number of Depositary Shares we ultimately elect to sell to the Selling Shareholder under the Purchase Agreement. If it
becomes necessary for us to issue and sell to the Selling Shareholder under the Purchase Agreement more than the 350,000,000,000 Ordinary
Shares being registered for resale under this prospectus in order to receive aggregate gross proceeds equal to $35.0 million under
the Purchase Agreement, we must file with the SEC one or more additional registration statements to register under the Securities Act
the resale by the Selling Shareholder of any such additional Depositary Shares we wish to sell from time to time under the Purchase Agreement,
which the SEC must declare effective, in each case before we may elect to sell any additional Depositary Shares under the Purchase Agreement.

In addition, the Selling Shareholder
is not obligated to buy any Depositary Shares under the Purchase Agreement if such shares, when aggregated with all other securities then
benef